((({WATCH})))>Trump to sign ‘America First’ executive order on Covid-19 vaccines Tuesday…
- President Donald Trump is expected to sign an executive order on Tuesday designed to ensure that U.S. efforts to assist other countries in vaccinating their populations against Covid-19 take on a lower priority than domestic inoculations.
- In a call with reporters Monday afternoon, a senior administration official described the order as primarily a “reaffirmation of the president’s commitment to America First.”
- Additionally, the order directs a handful of government agencies, including the State Department and the United States Agency for International Development, to work together to help international partners and allies procure Covid vaccines, the official said.
- President Donald Trump is expected to sign an executive order on Tuesday designed to ensure that U.S. efforts to assist other countries in vaccinating their populations against Covid-19 take on a lower priority than domestic inoculations.
- In a call with reporters Monday afternoon, a senior administration official described the order as primarily a “reaffirmation of the president’s commitment to America First.” Additionally, the order directs a handful of government agencies, including the State Department and the United States Agency for International Development, to work together to help international partners and allies procure Covid vaccines, the official said.
- CNBC has not reviewed the proposed text of the executive order, which could prove to be largely symbolic. The plans for the executive order were earlier reported by Fox News.
- An administration official told NBC News on Monday that the timeline for providing foreign assistance will be shaped by supply and demand but is anticipated to begin in the second quarter. President-elect Joe Biden will take office on Jan. 20 and is likely to shape his own policy for obtaining and distributing Covid-19 vaccines, possibly limiting the impact of Trump’s order.
- Trump is expected to sign the order after delivering remarks at the start of a Covid-19 summit at the White House on Tuesday, a senior administration official said on Monday’s call. The event will feature talks with administration officials and drug distributors, who will discuss the process of reviewing vaccine candidates and distributing them, the official said.
- Trump has largely ignored the growing coronavirus crisis in recent weeks despite a surge in infections and a mounting death toll that has surpassed 2,000 fatalities per day, instead focusing on legal efforts to overturn the results of November’s presidential election.
- Nonetheless, the signing will come at a particularly critical phase of vaccine development.
- Trump will sign the order just days before the Food and Drug Administration meets, on Thursday, to review a promising vaccine made by Pfizer and German drugmaker BioNTech.
- That vaccine may be authorized for use as soon as the end of this week. The FDA will meet to discuss another candidate, made by Moderna, on Dec. 17.
- While some particularly vulnerable Americans could be vaccinated shortly after the vaccines are approved, officials are warning that it will take months for everyone who wants a vaccine to receive one.
- Health and Human Services Secretary Alex Azar pr
- https://www.kacwashington.org/upcoming/household-and-lifestyle/gratuit-online-2020-lazio-club-brugge-dove-vedere-gratis
https://www.kacwashington.org/upcoming/household-and-lifestyle/streaming-online-2020-lazio-club-brugge-dove-vedere-gratis-free-2020-today-live
https://www.kacwashington.org/upcoming/household-and-lifestyle/gratis-tv-lazio-club-brugge-in-diretta-streaming-2020
https://www.kacwashington.org/upcoming/household-and-lifestyle/streams-lazio-club-brugge-in-diretta-live-08-decembre-2020
https://www.kacwashington.org/upcoming/household-and-lifestyle/gratis-tv-lazio-club-brugge-in-diretta-uefa-champions
https://www.kacwashington.org/upcoming/household-and-lifestyle/gratuit-online-2020-zenit-bvb-brugge-dove-vedere-gratis
https://www.kacwashington.org/upcoming/household-and-lifestyle/streaming-online-2020-zenit-bvb-brugge-dove-vedere-gratis
https://www.kacwashington.org/upcoming/household-and-lifestyle/gratis-tv-zenit-gegen-bvb-brugge-in-diretta-streaming-2020
https://www.kacwashington.org/upcoming/household-and-lifestyle/streams-free-zenit-gegen-bvb-brugge-in-diretta-live-08-decembre-2020
https://www.kacwashington.org/upcoming/household-and-lifestyle/2020-grati-tv-zenit-bvb-brugge-in-diretta-uefa-champions - The FDA said data from Pfizer’s coronavirus vaccine trials was “consistent” with recommendations put forth by the agency for an emergency use authorization.
- FDA staff also said data submitted appeared to show the vaccine provided protection after the first dose.
- It added that two doses of the vaccine were “highly effective” in preventing confirmed cases of Covid-19.
WATCH NOW
VIDEO03:43
FDA says Pfizer Covid vaccine data did not raise safety concerns
The Food and Drug Administration said Tuesday that data from Pfizer’s coronavirus vaccine trials was consistent with recommendations put forth by the agency for an emergency use authorization. It also said the vaccine was highly effective and did not raise any specific safety concerns.
In documents published ahead of an advisory meeting Thursday to review Pfizer’s vaccine, FDA staff also said data submitted appeared to show the vaccine provided protection after the first dose. Pfizer’s vaccine recommends two doses about three weeks apart. The agency added that two doses of the vaccine were “highly effective” in preventing confirmed cases of Covid-19 at least seven days following the second dose.
“As such, FDA has determined that the Sponsor has provided adequate information to ensure the vaccine’s quality and consistency for authorization of the product under an EUA,” the agency said on its website.
The FDA is expected to decide on whether to authorize Pfizer’s vaccine within days. The U.K. on Tuesday began mass inoculations with the vaccine based on its approval of emergency use.
The documents posted Tuesday offer a glimpse of the FDA’s view of the vaccine. The agency is scheduled to convene a meeting of its Vaccines and Related Biological Products Advisory Committee, a group of outside medical experts, on Thursday to review Pfizer’s Covid-19 vaccine with German drugmaker BioNTech for emergency use.
Emergency use authorization means the FDA will allow some people to receive the vaccine as the agency continues to evaluate data. It isn’t the same as a full approval, which can typically take months. The FDA granted emergency clearance for Gilead Sciences’ remdesivir in May before giving full approval in late October.
If Thursday’s meeting goes well and the advisory committee formally recommends the vaccine, the FDA could announce its authorization “within days,” Health and Human Services Secretary Alex Azar told ABC News’ “This Week” on Sunday. “But it’s going to go according to FDA’s gold-standard process, and I’m going to make sure it does,” he added.
The FDA doesn’t have to follow the advisory committee’s recommendation, but the agency often does. Additionally, the FDA’s positive assessment of the vaccine does not mean the committee will take the same stance at its meeting Thursday.
Pfizer submitted its Covid vaccine data to the FDA on Nov. 20. The company said a final analysis of its phase three clinical trial, with more than 43,000 participants, found the vaccine was 95% effective in preventing Covid, was safe and appeared to fend off severe disease. Its vaccine uses messenger RNA, or mRNA, technology. It’s a new approach to vaccines that uses genetic material to provoke an immune response.
An authorization of the vaccine would be a pivotal moment in the pandemic, as public health officials say the U.S. is likely to face its worst public health crisis in history this winter. Hospitals across the U.S. already have a higher load of Covid patients than ever, and the country’s outbreak is primed to set even more grim records this week.
U.S. officials say they will distribute the vaccine within 24 hours of authorization. Initial doses of the vaccine will be limited as manufacturing ramps up, with top U.S. health officials predicting it will take months to immunize everyone who wants to be vaccinated against Covid in the U.S. The vaccine will likely be distributed in phases, with the Centers for Disease Control and Prevention prioritizing health-care workers and nursing homes.
There is currently insufficient data to make conclusions about the safety of the vaccine in children under age 16, pregnant women and people with compromised immune systems, the FDA said Tuesday.